Risk Estimation for Recurrent Clostridium difficile Infection Based on Clinical Factors

被引:68
作者
D'Agostino, Ralph B., Sr. [1 ]
Collins, Sylva H. [2 ]
Pencina, Karol M. [1 ]
Kean, Yin
Gorbach, Sherwood [2 ]
机构
[1] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA
[2] Cubist Pharmaceut, Lexington, MA USA
关键词
Clostridium difficile infection; CDI; fidaxomicin; vancomycin; INTEGRATED DISCRIMINATION; NET RECLASSIFICATION; VANCOMYCIN; EPIDEMIOLOGY; FIDAXOMICIN; DIARRHEA; DISEASE; METRONIDAZOLE; MANAGEMENT; CARE;
D O I
10.1093/cid/ciu107
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The incidence of Clostridium difficile infection (CDI) has risen dramatically during the last decade. Although patients respond well to medical therapy such as vancomycin, 20%-30% of patients treated suffer a recurrence of CDI. Methods. We developed a simple/practical scoring rule (logistic regression model) for recurrent CDI using data from 2 large phase 3 clinical trials. Seventy-seven baseline CDI factors were classified: demographics, comorbidity, medications, vital signs, laboratory tests, severity, and symptoms. Predictors with the highest discrimination in each class (using receiver operating characteristics curve) were selected. For the final model, stepwise selection was performed. Discrimination, calibration, and internal validation were used to assess the model. Results. The final model with a simple scoring rule was developed. It includes 4 independent risk factors that are readily available when the patient makes initial contact: age (<75 vs >= 75 years), number of unformed bowel movements during previous 24 hours (<10 vs >= 10), serum creatinine leves (< 1.2 mg/dL vs >= 1.2 mg/dL) and prior episode of CDI (yes vs no). In addition, the model includes choice of treatment (vancomycin or fidaxomicin). Conclusions. The prediction model for recurrence may be useful for treatment decision.
引用
收藏
页码:1386 / 1393
页数:8
相关论文
共 50 条
  • [31] Recurrent Clostridium difficile infection: causality and therapeutic approaches
    Johnson, Stuart
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 33 : S33 - S36
  • [32] Clinical characterization and risk factors of Clostridium difficile infection in elderly patients in a Chinese hospital
    Zhang Lihua
    Dong Danfeng
    Jiang Cen
    Wang Xuefeng
    Peng Yibing
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2015, 9 (04): : 381 - 387
  • [33] Clostridium difficile: Changing Epidemiology, Treatment and Infection Prevention Measures
    Cecil, Jane A.
    CURRENT INFECTIOUS DISEASE REPORTS, 2012, 14 (06) : 612 - 619
  • [34] Cost-effectiveness of Competing Strategies for Management of Recurrent Clostridium difficile Infection: A Decision Analysis
    Konijeti, Gauree G.
    Sauk, Jenny
    Shrime, Mark G.
    Gupta, Meera
    Ananthakrishnan, Ashwin N.
    CLINICAL INFECTIOUS DISEASES, 2014, 58 (11) : 1507 - 1514
  • [35] Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada
    Wagner, Monika
    Lavoie, Louis
    Goetghebeur, Mireille
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2014, 25 (02) : 87 - 94
  • [36] Antimicrobial Use and Risk for Recurrent Clostridium difficile Infection
    Drekonja, Dimitri M.
    Amundson, William H.
    DeCarolis, Douglas D.
    Kuskowski, Michael A.
    Lederle, Frank A.
    Johnson, James R.
    AMERICAN JOURNAL OF MEDICINE, 2011, 124 (11) : 1081.e1 - 1081.e7
  • [37] Clinical predictors of recurrent Clostridium difficile infection in out-patients
    Shivashankar, R.
    Khanna, S.
    Kammer, P. P.
    Harmsen, W. Scott
    Zinsmeister, A. R.
    Baddour, L. M.
    Pardi, D. S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (05) : 518 - 522
  • [38] Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection
    Sheitoyan-Pesant, Caroline
    Abou Chakra, Claire Nour
    Pepin, Jacques
    Marcil-Heguy, Anais
    Nault, Vincent
    Valiquette, Louis
    CLINICAL INFECTIOUS DISEASES, 2016, 62 (05) : 574 - 580
  • [39] Fidaxomicin - the new drug for Clostridium difficile infection
    Vaishnavi, Chetana
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2015, 141 : 398 - 407
  • [40] Recurrent Clostridium difficile infections: The importance of the intestinal microbiota
    Terrier, Marie Celine Zanella
    Simonet, Martine Louis
    Bichard, Philippe
    Frossard, Jean Louis
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (23) : 7416 - 7423